GUO LABORATORY 
Aging, Alzheimer's Disease, Biomarker, Neuroimaging

CN
Our new paper was published in Neurology Journal as Research Article (March 17, 2024)
Posted onMar 18,2024


image.png

Dr. Yue Cai's latest paper was published on the  Neurology Journal . 

Plasma β-amyloid42 (Aβ42)/Aβ40 levels have shown promise in identifying Aβ-PET positive

individuals. This study explored the concordance and discordance of plasma Aβ42/Aβ40 positivity

(Plasma±) with CSF Aβ42/Aβ40 positivity (CSF±) and Aβ-PET positivity (PET±) in

older adults without dementia. Associations of Aβ deposition, cortical thickness, glucose metabolism,

and microglial activation were also investigated.


We selected participants without dementia who had concurrent plasma Aβ42/Aβ40 and Aβ-

PET scans from the Alzheimer’s Disease Neuroimaging Initiative cohort. Participants were

categorized into Plasma±/PET± based on thresholds of composite 18F-florbetapir (FBP)

standardized uptake value ratio (SUVR) ≥1.11 and plasma Aβ42/Aβ40 ≤0.1218. Aβ-PET–

negative individuals were further divided into Plasma±/CSF± (CSF Aβ42/Aβ40 ≤0.138), and

the concordance and discordance of Aβ42/Aβ40 in the plasma and CSF were investigated.

Baseline and slopes of regional FBP SUVR were compared among Plasma±/PET± groups,

and associations of regional FBP SUVR, FDG SUVR, cortical thickness, and CSF soluble

Triggering Receptor Expressed on Myeloid Cell 2 (sTREM2) levels were analyzed.


One hundred eighty participants (mean age 72.7 years, 51.4% female, 96 cognitively unimpaired, and

84 with mild cognitive impairment) were included.We found that the proportion of Plasma+/PET−

individuals was 6.14 times higher (odds ratio (OR) = 6.143, 95% confidence interval (CI)

2.740–16.185, p < 0.001) than that of Plasma-/PET+ individuals, and Plasma+/CSF− individuals

showed 8.5 times larger percentage (OR = 8.5, 95% CI: 3.031–32.974, p < 0.001) than Plasma-/

CSF+ individuals in Aβ-PET–negative individuals. Besides, Plasma+/PET- individuals exhibited

faster (p < 0.05) Aβ accumulation predominantly in bilateral banks of superior temporal sulcus

(BANKSSTS) and supramarginal, and superior parietal cortices compared with Plasma−/PET−

individuals, despite no difference in baseline FBP SUVRs. In Plasma+/PET+ individuals, higher CSF

sTREM2 levels correlated with slower BANKSSTS Aβ accumulation (standardized β (βstd) =

−0.418, 95% CI −0.681 to −0.154, p = 0.002). Conversely, thicker cortical thickness and higher

glucose metabolism in supramarginal and superior parietal cortices were associated with faster (p <

0.05) CSF sTREM2 increase in Plasma+/PET- individuals rather than in Plasma+/PET+ individuals.

These findings suggest that plasma Aβ42/Aβ40 abnormalities may predate CSF Aβ42/Aβ40 and

Aβ-PET abnormalities. Higher sTREM2-related microglial activation is linked to thicker cortical

thickness and higher metabolism in early amyloidosis stages but tends to mitigate Aβ

accumulation primarily at relatively advanced stages.